About: Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
Creator	Munster, Vincent Feldmann, Friederike Saturday, Greg Cihlar, Tomas Okumura, Atsushi Scott, Dana Schwarz, Benjamin Martens, Craig Bosio, Catharine Meade-White, Kimberly De Wit, Emmie Porter, Danielle Williamson, Brandi Leighton, Ian Lovaglio, Jamie Yinda, Kwe Schulz, Jonathan Anzick, Sarah Barbian, Kent Claude, ; Hanley, W Lizzette Pérez-Pérez, ; Neeltje Van Doremalen, Bsc Patrick, Dvm
source	BioRxiv; Medline
abstract	Background Effective therapeutics to treat COVID-19 are urgently needed. Remdesivir is a nucleotide prodrug with in vitro and in vivo efficacy against coronaviruses. Here, we tested the efficacy of remdesivir treatment in a rhesus macaque model of SARS-CoV-2 infection. Methods To evaluate the effect of remdesivir treatment on SARS-CoV-2 disease outcome, we used the recently established rhesus macaque model of SARS-CoV-2 infection that results in transient lower respiratory tract disease. Two groups of six rhesus macaques were infected with SARS-CoV-2 and treated with intravenous remdesivir or an equal volume of vehicle solution once daily. Clinical, virological and histological parameters were assessed regularly during the study and at necropsy to determine treatment efficacy. Results In contrast to vehicle-treated animals, animals treated with remdesivir did not show signs of respiratory disease and had reduced pulmonary infiltrates on radiographs. Virus titers in bronchoalveolar lavages were significantly reduced as early as 12hrs after the first treatment was administered. At necropsy on day 7 after inoculation, lung viral loads of remdesivir-treated animals were significantly lower and there was a clear reduction in damage to the lung tissue. Conclusions Therapeutic remdesivir treatment initiated early during infection has a clear clinical benefit in SARS-CoV-2-infected rhesus macaques. These data support early remdesivir treatment initiation in COVID-19 patients to prevent progression to severe pneumonia.
has issue date	2020-04-22(xsd:dateTime)
bibo:doi	10.1101/2020.04.15.043166
bibo:pmid	32511319
has license	biorxiv
sha1sum (hex)	df24446f915775813e690afe0facac666ad6bb14
schema:url	https://doi.org/10.1101/2020.04.15.043166
resource representing a document's title	Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
has PubMed identifier	32511319
schema:publication	bioRxiv
resource representing a document's body	covid:df24446f915775813e690afe0facac666ad6bb14#body_text
is schema:about of	named entity 'rhesus macaques' named entity 'infection' named entity 'COVID-19' named entity 'coronaviruses' named entity 'infection' named entity 'SARS-CoV-2' named entity 'remdesivir' named entity 'titer' named entity 'SARS-CoV-2' named entity 'coronaviruses' named entity 'coronaviruses' named entity 'NIH' named entity 'Virus' named entity 'lungs' named entity 'remdesivir' named entity 'real-time RT-PCR' named entity 'homogenate' named entity 'alveolar' named entity 'virus' named entity 'remdesivir' named entity 'maintenance dose' named entity 'penicillin' named entity 'remdesivir' named entity 'ileum' named entity 'SARS-CoV-2' named entity 'mass spectrometer' named entity 'BSL3' named entity 'SARS-CoV' named entity 'intravenous' named entity 'respiratory tract' named entity 'methanol' named entity 'prodrug' named entity 'homogenate' named entity 'coronaviruses' named entity 'inoculation' named entity 'signal pairs' named entity 'viral RNA' named entity 'pathology' named entity 'titration' named entity 'radiographs' named entity 'SARS-CoV-2' named entity 'remdesivir' named entity 'antigen' named entity 'serum' named entity 'interstitial pneumonia' named entity 'remdesivir' named entity 'inoculation' named entity 'Radiographic' named entity 'acetic acid' named entity 'Limit of quantification' named entity 'lung tissue' named entity 'virus replication' named entity 'rhesus macaque' named entity 'immunohistochemistry' named entity 'qRT-PCR' named entity 'lung lobes' named entity 'ad libitum' named entity 'remdesivir' named entity 'ventro-dorsal'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software